litlas
Log inCreate account

Philippe Armand

Active 1997–2025

171
Papers
32,566
Citations
90
h-index
169
i10-index

Citations

Citations per year for Philippe Armand1997: 1 citations1998: 8 citations1999: 19 citations2000: 10 citations2001: 30 citations2002: 4 citations2003: 12 citations2004: 9 citations2005: 18 citations2006: 17 citations2007: 20 citations2008: 32 citations2009: 39 citations2010: 44 citations2011: 44 citations2012: 70 citations2013: 100 citations2014: 147 citations2015: 307 citations2016: 389 citations2017: 539 citations2018: 511 citations2019: 1,581 citations2020: 1,879 citations2021: 1,845 citations2022: 1,149 citations2023: 911 citations2024: 1,330 citations2025: 593 citations2026: 7 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,908 citing papers, 28.8% of this breakdownChina: 1,277 citing papers, 9.4% of this breakdownGermany: 859 citing papers, 6.3% of this breakdownItaly: 776 citing papers, 5.7% of this breakdownFrance: 754 citing papers, 5.6% of this breakdownUnited Kingdom: 708 citing papers, 5.2% of this breakdownSpain: 495 citing papers, 3.7% of this breakdownJapan: 457 citing papers, 3.4% of this breakdownCanada: 437 citing papers, 3.2% of this breakdownNetherlands: 358 citing papers, 2.6% of this breakdownAustralia: 336 citing papers, 2.5% of this breakdownSwitzerland: 316 citing papers, 2.3% of this breakdown
0%28.8%Other 21.3%

Institutions

Fields

  • Medicine78.2%
  • Immunology and Microbiology11.4%
  • Biochemistry, Genetics and Molecular Biology8.7%
  • Engineering0.4%
  • Materials Science0.3%
  • Neuroscience0.2%
  • Other0.8%

Topics

  • Cancer Immunotherapy and Biomarkers9.4%
  • CAR-T cell therapy research8.3%
  • Immune Cell Function and Interaction6.8%
  • Lymphoma Diagnosis and Treatment6.4%
  • Hematopoietic Stem Cell Transplantation5.1%
  • Acute Myeloid Leukemia Research3.6%
  • Other60.4%

Coauthors

All papers

Open in search
  1. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    Authors: Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C. Scott, Martin Gutierrez, Stephen J. Schuster, Michael Millenson, Deepika Cattry, Gordon J. Freeman, Scott J. Rodig, Bjoern Chapuy, Azra H. Ligon, Lili Zhu, Joseph F. Grosso, Su Young Kim, John M. Timmerman, Margaret A. Shipp, Philippe Armand - New England Journal of Medicine 2014 cited by 3,547

  2. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Amaka Achufusi, Philippe Armand, Meghan Berkenstock, Shailender Bhatia, Lihua E. Budde, Saurin Chokshi, Marianne Davies, Amro Elshoury, Yaron Gesthalter, Aparna Hegde, Michael D. Jain, Benjamin H. Kaffenberger, Melissa G. Lechner, Tianhong Li, Alissa Marr, Suzanne McGettigan, Jordan P. McPherson, Theresa Medina, Nisha Mohindra, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Pradnya D. Patil, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Vlad G. Zaha, Megan Lyons, Mary A. Dwyer, Lisa Hang - Journal of the National Comprehensive Cancer Network 2022 cited by 418

  3. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction

    Authors: Tomas G. Neilan, Thiago Quinaglia, Takeshi Onoue, Syed Mahmood, Zsófia D. Drobni, Hannah Gilman, Amanda M. Smith, Julius C. Heemelaar, Priya Brahmbhatt, Jor Sam Ho, Supraja Sama, Jakub Svoboda, Donna Neuberg, Jeremy S. Abramson, Ephraim P. Hochberg, Jefferey A. Barnes, Philippe Armand, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Jacob D. Soumerai, Yuchi Han, Robb S. Friedman, Ann S. LaCasce, Bonnie Ky, D. L. Landsburg, Sunita D. Nasta, Raymond Y. Kwong, Michael Jerosch‐Herold, Robert Redd, Lanqi Hua, James L. Januzzi, Aarti Asnani, Negareh Mousavi, Marielle Scherrer‐Crosbie - JAMA 2023 cited by 186

  4. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

    Authors: John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Benjamin H. Kaffenberger, Matthew A. Lunning, Suzanne McGettigan, Jordan P. McPherson, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Nathan A. Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2020 cited by 486

  5. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma

    Authors: Christopher J. Gibson, R. Coleman Lindsley, Vatche Tchekmedyian, Brenton G. Mar, Jiantao Shi, Siddhartha Jaiswal, Alysia Bosworth, Liton Francisco, Jianbo He, Anita Bansal, Elizabeth A. Morgan, Ann S. LaCasce, Arnold S. Freedman, David C. Fisher, Eric D. Jacobsen, Philippe Armand, Edwin P. Alyea, John Koreth, Vincent T. Ho, Robert J. Soiffer, Joseph H. Antin, Jerome Ritz, Sarah Nikiforow, Stephen J. Forman, Franziska Michor, Donna Neuberg, Ravi Bhatia, Ravi Bhatia, Benjamin L. Ebert - Journal of Clinical Oncology 2017 cited by 470

  6. Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines

    Authors: Carlos A. Gongora, Zsófia D. Drobni, Thiago Quinaglia Araujo Costa Silva, Amna Zafar, Jingyi Gong, Daniel A. Zlotoff, Hannah Gilman, Sarah Hartmann, Supraja Sama, Sofia Nikolaidou, Giselle Alexandra Suero‐Abreu, Eric N. Jacobsen, Jeremy S. Abramson, Ephraim P. Hochberg, J. R. Barnes, Philippe Armand, Paaladinesh Thavendiranathan, Anju Nohria, Tomas G. Neilan - JACC Heart Failure 2022 cited by 155

  7. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

    Authors: Caron A. Jacobson, Bradley D. Hunter, Robert Redd, Scott J. Rodig, Pei-Hsuan Chen, Kyle Wright, Mikel Lipschitz, Jerome Ritz, Yusuke Kamihara, Philippe Armand, Sarah Nikiforow, Michael Rogalski, Joseph Maakaron, Samantha Jaglowski, Marcela V. Maus, Yi‐Bin Chen, Jeremy S. Abramson, Justin Kline, Elizabeth Budde, Alex F. Herrera, Matthew Mei, Jonathon B. Cohen, Stephen D. Smith, David G. Maloney, Ajay K. Gopal, Matthew J. Frigault, Utkarsh Acharya - Journal of Clinical Oncology 2020 cited by 345

  8. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

    Authors: Jennifer L. Crombie, Tara Graff, Lorenzo Falchi, Yasmin Karimi, Rajat Bannerji, Loretta J. Nastoupil, Catherine Thiéblemont, Rénata Ursu, Nancy L. Bartlett, Victoria Nachar, J. Weiss, Jane Osterson, Krish Patel, Joshua Brody, Jeremy S. Abramson, Matthew A. Lunning, Nirav N. Shah, Ayed O. Ayed, Manali Kamdar, Benjamin M. Parsons, Paolo F. Caimi, Ian W. Flinn, Alex F. Herrera, Jeffrey P. Sharman, Marshall McKenna, Philippe Armand, Brad S. Kahl, Sonali M. Smith, Andrew D. Zelenetz, Lihua E. Budde, Martin Hutchings, Tycel Phillips, Michael Dickinson - Blood 2024 cited by 131

  9. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

    Authors: John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Brianna Hoffner, Christopher Hoimes, Mario E. Lacouture, Frederick L. Locke, Matthew A. Lunning, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen M. Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L. Scavone - Journal of the National Comprehensive Cancer Network 2019 cited by 560

  10. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

    Authors: Margaretha G.M. Roemer, Ranjana H. Advani, Azra H. Ligon, Yasodha Natkunam, Robert Redd, Heather Homer, Courtney Connelly, Heather H. Sun, Sarah E. Daadi, Gordon J. Freeman, Philippe Armand, Bjoern Chapuy, Daphne de Jong, Richard T. Hoppe, Donna Neuberg, Scott J. Rodig, Margaret A. Shipp - Journal of Clinical Oncology 2016 cited by 803

  11. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

    Authors: Philippe Armand, Andreas Engert, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Margaret A. Shipp, Kazunobu Kato, Anne Sumbul, Benedetto Farsaci, Stephen M. Ansell - Journal of Clinical Oncology 2018 cited by 754

  12. Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

    Authors: John Koreth, Ken‐ichi Matsuoka, Haesook T. Kim, Sean M. McDonough, Bhavjot Bindra, Edwin P. Alyea, Philippe Armand, Corey Cutler, Vincent T. Ho, Nathaniel S. Treister, Don C. Bienfang, Sashank Prasad, Dmitrios Tzachanis, Robin Joyce, David Avigan, Joseph H. Antin, Jerome Ritz, Robert J. Soiffer - New England Journal of Medicine 2011 cited by 1,117

  13. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

    Authors: Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, Emma Scott, Ahmad Halwani, Martin Gutierrez, Michael Millenson, Adam D. Cohen, Stephen J. Schuster, Daniel Lebovic, Madhav V. Dhodapkar, David Avigan, Bjoern Chapuy, Azra H. Ligon, Gordon J. Freeman, Scott J. Rodig, Deepika Cattry, Lili Zhu, Joseph F. Grosso, M. Brigid Garelik, Margaret A. Shipp, Ivan Borrello, John M. Timmerman - Journal of Clinical Oncology 2016 cited by 1,011

  14. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

    Authors: Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Yinghua Zhang, Alejandro D. Ricart, Arun Balakumaran, Craig H. Moskowitz, for the KEYNOTE-087 - Journal of Clinical Oncology 2017 cited by 985

  15. Ipilimumab for Patients with Relapse after Allogeneic Transplantation

    Authors: Matthew S. Davids, Haesook T. Kim, Pavan Bachireddy, Caitlin Costello, Rebecca Liguori, Alexandra Savell, Alexander Lukez, David Avigan, Yi‐Bin Chen, Peter A. McSweeney, Nicole R. LeBoeuf, Michael S. Rooney, Michaela Bowden, Chensheng W. Zhou, Scott R. Granter, Jason L. Hornick, Scott J. Rodig, Masahiro Hirakawa, Mariano Severgnini, F. Stephen Hodi, Catherine J. Wu, Vincent T. Ho, Corey Cutler, John Koreth, Edwin P. Alyea, Joseph H. Antin, Philippe Armand, Howard Streicher, Edward D. Ball, Jerome Ritz, Asad Bashey, Robert J. Soiffer - New England Journal of Medicine 2016 cited by 594

  16. Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy

    Authors: Metin Özdemirli, Thomas Loughney, Emre Deniz, Joeffrey Chahine, Maher Albitar, Stefania Pittaluga, Sam Sadigh, Philippe Armand, Aykut Uren, Kenneth C. Anderson - New England Journal of Medicine 2024 cited by 90

  17. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

    Authors: Margaretha G.M. Roemer, Robert Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Stephanie Sasse, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Stephen M. Ansell, Kazunobu Kato, Benedetto Farsaci, Anne Sumbul, Philippe Armand, Donna Neuberg, Geraldine S. Pinkus, Azra H. Ligon, Scott J. Rodig, Margaret A. Shipp - Journal of Clinical Oncology 2018 cited by 367

  18. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

    Authors: Philippe Armand, Haesook T. Kim, Brent R. Logan, Zhiwei Wang, Edwin P. Alyea, Matt Kalaycio, Richard T. Maziarz, Joseph H. Antin, Robert J. Soiffer, Daniel J. Weisdorf, J. Douglas Rizzo, Mary M. Horowitz, Wael Saber - Blood 2014 cited by 942

  19. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

    Authors: Bruce D. Cheson, Stephen M. Ansell, Larry Schwartz, Leo I. Gordon, Ranjana H. Advani, Heather A. Jacene, Axel Hoos, Sally F. Barrington, Philippe Armand - Blood 2016 cited by 506

  20. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma

    Authors: Lakshmi Nayak, Fábio M. Iwamoto, Ann S. LaCasce, Srinivasan Mukundan, Margaretha G.M. Roemer, Bjoern Chapuy, Philippe Armand, Scott J. Rodig, Margaret A. Shipp - Blood 2017 cited by 459

  21. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

    Authors: Stephen M. Ansell, Monique C. Minnema, Peter Johnson, John M. Timmerman, Philippe Armand, Margaret A. Shipp, Scott J. Rodig, Azra H. Ligon, Margaretha G.M. Roemer, Nishitha Reddy, Jonathon B. Cohen, Sarit Assouline, Michelle Poon, Manish Sharma, Kazunobu Kato, Selda Samakoglu, Anne Sumbul, Andrew Grigg - Journal of Clinical Oncology 2019 cited by 363

  22. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

    Authors: Nancy L. Bartlett, Alex F. Herrera, Eva Domingo‐Doménech, Amitkumar Mehta, Andres Forero‐Torres, Ramón García‐Sánz, Philippe Armand, Sumana Devata, Antonia Rodríguez Izquierdo, Izidore S. Lossos, Craig B. Reeder, Taimur Sher, Robert Chen, Sylvia E. Schwarz, Leila Alland, András Strassz, Kim Prier, Cassandra Choe-Juliak, Stephen M. Ansell - Blood 2020 cited by 151

  23. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma

    Authors: Matthew J. Frigault, Jörg Dietrich, Maria Martinez‐Lage, Mark B. Leick, Bryan D. Choi, Zachariah DeFilipp, Yi‐Bin Chen, Jeremy S. Abramson, Jennifer L. Crombie, Philippe Armand, Lakshmi Nayak, Chris Panzini, Lauren S. Riley, Kathleen Gallagher, Marcela V. Maus - Blood 2019 cited by 237

  24. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Authors: Anas Younes, Armando Santoro, Margaret A. Shipp, Pier Luigi Zinzani, John M. Timmerman, Stephen M. Ansell, Philippe Armand, Michelle A. Fanale, Voravit Ratanatharathorn, John Kuruvilla, Jonathon B. Cohen, Graham P. Collins, Kerry J. Savage, Marek Trněný, Kazunobu Kato, Benedetto Farsaci, Susan Parker, Scott J. Rodig, Margaretha G.M. Roemer, Azra H. Ligon, Andreas Engert - The Lancet Oncology 2016 cited by 924